MEDDDICAL has announced real-world data analysis and health market intelligence advisory services for MedTech and pharmaceutical companies developing new products for the market.

Sotogrande, Spain, October 20, 2026 /NewsNetwork/ -- MEDDDICAL has announced that it will be offering advisory services to MedTech organisations and pharmaceutical companies in need of real-world evidence (RWE) analysis for product development. The announcement comes in the wake of accelerating AI integration into data analysis in the medical field, and MEDDDICAL aims to help its partners understand the growing complexity of AI-powered analytics and ensure RWE aligns with their use cases.

For more information, please visit https://medddical.com/

According to IQVIA's "MedTech Trends Shaping 2026" report, published in February 2026, the use of real-world evidence in MedTech has been growing quickly, and advances in AI are expected to strengthen how that evidence is analysed this year. The report notes that established AI techniques such as natural language processing can produce "higher-grade evidence" by pulling device details, clinical data points, and patient factors out of unstructured healthcare records. Regulators are also making this kind of data easier to use. In December 2025, the FDA finalized updated guidance that allows sponsors to use aggregate or de-identified data when submitting real-world evidence for medical devices.

With AI-powered tools reshaping how RWE is generated and used for decision-making, MEDDDICAL emphasises that MedTech organisations must use traceable, high-quality, and verified datasets that align with their focus area. Part of MEDDDICAL’s services involve defining the evidence that is needed for actionable strategic intelligence, including evaluating predictive modelling approaches and identifying the analytical frameworks most suitable for its partners’ objectives.

"MedTech teams are under growing pressure to show payers real-world value, and AI has made it much faster to analyse the data behind that evidence," said Alexander Müller, founder of MEDDDICAL. "Speed doesn't help if the dataset doesn't fit the question. Before a MedTech company licenses data or commits to an analytics approach, we help it work out which sources and methods suit its device, its market, and the payers it needs to convince. Getting that right at the start can save months of work and a significant share of the evidence budget."

MEDDDICAL adds that licensing the wrong dataset can significantly impact production, resulting in wasted expenditures and time. For this reason, the advisory believes that independent health market intelligence advisors are vital for MedTech organisations with specific clinical or commercial goals.

About MEDDDICAL

MEDDDICAL is a leading health market intelligence advisory that works with pharmaceutical partners to accelerate drug development and market access. With a multidisciplinary team of health economists, statisticians, and data scientists, MEDDDICAL specialises in analysing real-world evidence for its partners to facilitate better health outcomes for patients around the world.

More information is available at https://medddical.com/

Contact Info:
Name: Rainer Muller
Email: Send Email
Organization: MEDDDICAL
Address: Aptos 221 Edificio D2C, Sotogrande, Cadiz 11310, Spain
Website: https://medddical.com

Source: NewsNetwork

Release ID: 89206703

In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.